- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02710240
Indocyanine Green for Central Nervous System Tumors
A Pilot/Feasibility Study of Intraoperative Image-Guided Surgery of CNS Tumors With Indocyanine Green and MR Spectroscopic Imaging
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Abramson Cancer Center of the University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adult patients 18 years of age and older Patients presenting with a CNS tumor presumed to be resectable and are at risk for local recurrence on pre-operative assessment Good operative candidate as determined by the treating physician and multidisciplinary team Subject capable of giving informed consent and participating in the process of consent
Exclusion Criteria:
Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery Subjects with a history of iodide allergies Vulnerable patient populations Patients unable to participate in the consent process (children and neonates) Patients with non-MRI compatible implanted metallic foreign bodies Patients who due to severe claustrophobia cannot tolerate MRI scanning Patients with a known allergy or hypersensitivity to MRI contrast agents including gadolinium
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ICG Arm
Subjects undergo indocyanine green injection within 72 hours prior to surgery.
Permitting infusion time within 72 hours of operation is believed to be adequate for tissue glow/surgical visualization.
Alternately, patients may receive 25 mg of indocyanine green during induction.
Dose and time of administration will be determined by the neurosurgeon during surgical planning.
This 25 mg dose of indocyanine green is similar to dosing for other intraoperative vascular visualization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity (SBR)
Time Frame: 72 hours
|
sensitivity of delayed, high dose indocyanine green (second window ICG), as measured by the signal-to-background ratio (SBR)
|
72 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: John Lee, MD, Abramson Cancer Center of the University of Pennsylvania
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 09315
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Suspected Central Nervous System Tumors
-
Centre Hospitalier Universitaire DijonCompletedInflamed Meninges | Suspected Meningitis | VentriculitisFrance
-
Children's Hospital of Fudan UniversityNanfang Hospital of Southern Medical University; Guangzhou Women and Children... and other collaboratorsRecruitingNeonatal Encephalopathy | Suspected Neonatal EncephalopathyChina
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
-
University Hospital, Basel, SwitzerlandRecruitingAdult Patients With Suspected Meningitis and/or EncephalitisSwitzerland
-
Brian LallyCompletedBrain and Central Nervous System TumorsUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Rabin Medical CenterUnknownCentral Nervous System Tumors | TumorsIsrael
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
Clinical Trials on Indocyanine Green (ICG)
-
University of PennsylvaniaCompleted
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Massachusetts General HospitalNational Cancer Institute (NCI); Dana-Farber Cancer Institute; Damon Runyon Cancer...CompletedColorectal Polyps | High Risk Polyposis Syndrome | Distal Colonic LesionsUnited States
-
Birmingham Women's and Children's NHS Foundation...Children's Cancer and Leukaemia GroupNot yet recruitingRenal Cancer | Wilms TumorUnited Kingdom
-
Xiang'an Hospital of Xiamen UniversityRecruitingBreast Cancer | Sentinel Lymph NodeChina
-
University of AarhusNovo Nordisk A/SUnknownSecondary LymphedemaDenmark
-
Jules Bordet InstituteCompletedColorectal Cancer | Peritoneal CarcinomatosisBelgium
-
Jules Bordet InstituteCompleted
-
Intuitive SurgicalUniversity Hospital, Geneva; Azienda Ospedaliera SS. Antonio e Biagio e Cesare...CompletedGallstones | Biliary Colic | Gallbladder DiseaseItaly, Switzerland
-
Laval UniversityCiusss de L'Est de l'Île de MontréalTerminatedGastric Cancer | Gastric Adenocarcinoma | Peritoneal Carcinomatosis | Peritoneal MetastasesCanada